Oral bisphosphonate-related osteonecrosis of the jaws: Favorable outcome after bisphosphonate holiday

Quintessence International

Volumn 40, Issue 4, 2009, Pages 277-278

  Kwon, Yong Dae ^a   Kim, Young Ran ^a   Choi, Byung Joon ^a   Lee, Deok Won ^a   Kim, Deog Yoon ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Bisphosphonate; CTX; Osteonecrosis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

AGED; ARTICLE; BLOOD; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; FEMALE; HUMAN; JAW DISEASE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MANDIBULAR DISEASES; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 67649774569     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66: 100-103.
2. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410.